FindTrial
Sign In

N/A - AFINF2

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-002228-42-FR
Enrollment
Unknown
Registered
2011-08-29
Start date
Unknown
Completion date
Unknown
Last updated
2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 14.0 Level: PT Classification code 10029268 Term: Neurofibromatosis System Organ Class: 10010331 - Congenital, familial and genetic disorders

Interventions

Trade Name: Afinitor Product Name: Afinitor Pharmaceutical Form: Tablet INN or Proposed INN: Evérolimus Other descriptive name: RAD001 Concentration unit: mg milligram(s) Concentration type: equal Con

Sponsors

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

France

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026